Dissecting bortezomib: development, application, adverse effects and future direction

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Bortezomib is a first-in-class proteasome inhibitor.
• It is approved for multiple myeloma and mantle cell lymphoma.
• Its use is being explored for solid cancers and stem cell transplantation.

Purpose of the Study:

• To comprehensively review bortezomib's development and therapeutic mechanisms.
• To discuss challenges including adverse effects and drug resistance.
• To explore next-generation proteasome inhibitors and future research directions.

Main Methods:

• Literature review of bortezomib's clinical application and research.
• Analysis of mechanisms of action, resistance, and adverse events.
• Discussion of emerging therapeutic strategies and future prospects.

Main Results:

• Bortezomib demonstrates significant efficacy in hematological malignancies.
• Adverse effects and the development of drug resistance pose challenges.
• Ongoing research focuses on overcoming resistance and expanding bortezomib's therapeutic utility.

Conclusions:

• Bortezomib remains a vital therapeutic agent, but challenges require further investigation.
• Understanding resistance mechanisms is crucial for optimizing treatment.
• Future research aims to develop more effective proteasome inhibitors and combination therapies.